Key result
Novel lipid-lowering therapies, including PCSK9 inhibitors, bempedoic acid, and antisense oligonucleotides, target specific parameters of lipid metabolism to effectively manage dyslipidemia in patients inadequately controlled by standard treatments.
Why the study?
Dyslipidemias pose significant risks for cardiovascular disease, creating a need to consolidate information on emerging therapies with the potential to significantly advance dyslipidemia management.
Do novel lipid-lowering therapies improve lipid profiles and cardiovascular risk in patients with dyslipidemia?
Do novel lipid-lowering therapies improve lipid profiles and cardiovascular risk in patients with dyslipidemia?
This review outlines the evolving landscape of dyslipidemia treatment, highlighting novel pharmacological agents that offer targeted alternatives for high-risk patients not reaching lipid goals on conventional therapies.
May support targeted options in refractory dyslipidemia; leaves open confirmation of cardiovascular outcome benefits.
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
No takes yet. Share an insight, caveat, or question.
Dybiec et al. (2023) conducted a review in Dyslipidemia. Novel lipid-lowering therapies (e.g., PCSK9 inhibitors, bempedoic acid, ASOs, APOC3 inhibitors, ANGPTL inhibitors, lomitapide) was evaluated. Novel lipid-lowering therapies, including PCSK9 inhibitors, bempedoic acid, and antisense oligonucleotides, target specific parameters of lipid metabolism to effectively manage dyslipidemia in patients inadequately controlled by standard treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: